Medtronic Drug-Eluting Stent Trial Aims For Equivalency, Approval In 2005
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's U.S. pivotal study of its rapamycin analog-eluting stent will randomize patients to Johnson & Johnson/Cordis' siroliumus-eluting Cypher in the control arm